Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Gilead Sciences (GILD) based on latest 13F filings. 6 funds buying, 6 selling — a perfectly split institutional landscape.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
Gilead Sciences has quietly become one of the most important biopharmaceutical companies in the world. Best known for its revolutionary hepatitis C cures (Sovaldi, Harvoni) and its HIV franchise (Biktarvy, Descovy), Gilead has more recently expanded into oncology through its acquisition of Immunomedics and the blockbuster cancer drug Trodelvy. The company generates massive free cash flow, pays a solid dividend, and has been one of the steadier performers in the volatile biotech sector.
The latest 13F filings reveal an evenly divided institutional landscape: 6 funds are buying and 6 are selling, with 4 holding steady. This perfect split creates an unusual tension — but the dollar amounts tell a much more nuanced story, with buyers deploying significantly larger capital than sellers.
Quick Answer
Across the funds we read directly from SEC filings, the largest Gilead position in the Q2 2026 13Fs (period ending 30 June 2026) is Citadel Advisors at $440M (3,480,444 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Renaissance Technologies, where Gilead is 0.4% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Gilead Sciences Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 6 |
| Funds Selling | 6 |
| Funds Holding | 4 |
| Active Funds Tracked | 16 |
A 6-to-6 buy-sell ratio looks balanced on the surface, but the scale of buying dwarfs the selling. The top three buyers alone — Vanguard, Fidelity, and State Street — hold a combined $34.5 billion in Gilead stock and all increased their positions. The sellers are trimming relatively smaller allocations. This is a classic case where the headline ratio masks a strongly bullish undercurrent.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho holds Gilead, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Citadel Advisors | $440M | 3,480,444 | 0.3% of $171.84B |
| Renaissance Technologies | $280M | 2,217,376 | 0.4% of $72.62B |
| Millennium Management | $184M | 1,458,924 | 0.1% of $142.92B |
| Bridgewater Associates | $37M | 290,881 | 0.2% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Gilead that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Who added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Bridgewater Associates | 180,737 | 290,881 | +61% |
| Millennium Management | 1,180,760 | 1,458,924 | +24% |
| Citadel Advisors | 3,982,185 | 3,480,444 | -13% |
| Renaissance Technologies | 2,152,528 | 2,217,376 | +3% |
A fund absent from this table reported no Gilead position in either quarter.
Related Articles
- Who Is Buying Moderna? Hedge Fund Activity in 2026
- Who Is Buying Regeneron? Hedge Fund Activity in 2026
- Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026
FAQ
Which hedge funds are buying Gilead Sciences right now?
Index managers such as Vanguard, BlackRock and State Street hold the largest raw positions in almost every large-cap name, because they track the index rather than pick the stock. Among the active filers we read directly from EDGAR, the largest position in the Q2 2026 filings is Citadel Advisors at $440M (3,480,444 shares).
Why is Gilead's HIV franchise important to institutional investors?
Biktarvy and Descovy generate predictable, high-margin cash flows that anchor Gilead's balance sheet and dividend. 13F commentary across active managers often cites the HIV franchise as the "fortress" that funds the oncology and cell-therapy expansion, which is why many institutions are comfortable holding the stock through cycles.
How does oncology fit into the institutional thesis on GILD?
Through the Immunomedics acquisition and Trodelvy, Gilead has built a meaningful oncology business that institutional analysts view as a growth optionality on top of stable HIV revenue. Buying from biotech-specialist Baker Bros Advisors is often interpreted as confirmation that the pipeline has more value than the current share price reflects.
What about biosimilar and patent-cliff risk?
Biosimilar pressure on legacy hepatitis C drugs and eventual loss of exclusivity on older HIV products are part of the bear case, and the six selling funds may be expressing that concern. 13F data does not show wholesale exits, however — sellers trimmed positions while remaining meaningfully invested.
Is this analysis a recommendation to act on GILD?
No. 13F snapshots describe what institutions reported owning at the end of the quarter and can lag real-time decisions by weeks. The page is informational and should be combined with personal research, time horizon and risk tolerance before any investment decision.